fosun pharma won acfic science and technology innovation award-凯发k8娱乐app下载

fosun pharma won acfic science and technology innovation award-凯发k8娱乐app下载

2014-02-27

fosun pharma won acfic science and technology innovation award

recently, all-china federation of industry & commerce published the science and technology innovation awards 2013 according to the regulations of all-china federation of industry & commerce science & technology awarding methods (interim). through the process of recommendation from regional federation of industry & commerce, expert evaluation, publication and acfic chairperson office approval, fosun pharma was awarded the science and technology innovation award because of its long-term practice in science and technology innovation. meanwhile, a total of 38 enterprises including sichuan kechuang medicine group and jinggong group have also won the awards, out of which six enterprises are from shanghai.


in order to perform well as an assistant of government to manage no public-owned economy, to play the role of promoting no public-owned economy growth, and to encourage the innovation of enterprises and technical staff, acfic set up the acfic science and technology innovation awards. it aims to recognize and encourage those enterprises, technical staff and entrepreneurs with technology innovation and science development, with the hope that these awarded enterprises will continue their exploration with innovative spirit for a health economic development with the integration of science & technology innovation and economic growth.


fosun pharma always considers innovation as the key power of development. focusing on innovative r&d, fosun pharma has raised the “original and generic co-development” drug r&d system. through the continuous investment into the “4 1” r&d platform, fosun pharma encourages the r&d innovation and new product launching. moreover, its r&d capability has been recognized by the international market. in october 2013, fosun pharma announced the cooperation with sellas on new drug r&d and transferred the marketing and further development rights for two new products which were developed independently by itself.